• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

亚洲淋巴瘤研究组的新发现：聚焦于T细胞和NK细胞淋巴瘤。

Novel findings from the Asian Lymphoma Study Group: focus on T and NK-cell lymphomas.

作者信息

Chan Jason Yongsheng, Lim Soon Thye

机构信息

Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.

Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.

出版信息

Int J Hematol. 2018 Apr;107(4):413-419. doi: 10.1007/s12185-018-2406-6. Epub 2018 Jan 29.

DOI:10.1007/s12185-018-2406-6
PMID:29380182
Abstract

T and NK-cell lymphomas are aggressive neoplasms with a unique epidemiological distribution, demonstrating higher prevalence in Asian countries compared to the West. Through the efforts of international collaboration, significant progress has been made especially on the biological understanding and clinical management of rare lymphoma subtypes including NK/T-cell lymphomas and monomorphic epitheliotropic intestinal T-cell lymphoma. In this review, we summarize the current status of lymphoma research conducted by the Asian Lymphoma Study Group and highlight key updates on the advancement of T and NK-cell lymphoma research.

摘要

T细胞和NK细胞淋巴瘤是具有独特流行病学分布的侵袭性肿瘤，与西方相比，在亚洲国家的患病率更高。通过国际合作的努力，特别是在包括NK/T细胞淋巴瘤和单形性嗜上皮性肠道T细胞淋巴瘤在内的罕见淋巴瘤亚型的生物学认识和临床管理方面取得了重大进展。在本综述中，我们总结了亚洲淋巴瘤研究组进行的淋巴瘤研究现状，并强调了T细胞和NK细胞淋巴瘤研究进展的关键更新。

相似文献

1
Novel findings from the Asian Lymphoma Study Group: focus on T and NK-cell lymphomas.亚洲淋巴瘤研究组的新发现：聚焦于T细胞和NK细胞淋巴瘤。
Int J Hematol. 2018 Apr;107(4):413-419. doi: 10.1007/s12185-018-2406-6. Epub 2018 Jan 29.
2
Classification of cell lineage and anatomical site, and prognosis of extranodal T-cell lymphoma -- natural killer cell, cytotoxic T lymphocyte, and non-NK/CTL types.结外T细胞淋巴瘤——自然杀伤细胞、细胞毒性T淋巴细胞及非NK/CTL型的细胞谱系、解剖部位分类及预后
Virchows Arch. 2002 Apr;440(4):425-35. doi: 10.1007/s00428-001-0545-1. Epub 2001 Dec 6.
3
Therapeutic outcome of Epstein-Barr virus positive T/NK cell lymphoma in the upper aerodigestive tract.上呼吸道消化道中爱泼斯坦-巴尔病毒阳性T/NK细胞淋巴瘤的治疗结果
Yonsei Med J. 2002 Apr;43(2):175-82. doi: 10.3349/ymj.2002.43.2.175.
4
Diagnosis and management of natural killer-cell malignancies.自然杀伤细胞恶性肿瘤的诊断与治疗。
Expert Rev Hematol. 2010 Oct;3(5):593-602. doi: 10.1586/ehm.10.51.
5
Nasal and nasal-type natural killer (NK)/T-cell lymphoma: immunophenotype and Epstein-Barr virus (EBV) association.鼻及鼻型自然杀伤（NK）/T细胞淋巴瘤：免疫表型与EB病毒（EBV）关联
Med J Malaysia. 2003 Jun;58(2):196-204.
6
Intestinal T-cell and natural killer-cell lymphomas in Taiwan with special emphasis on 2 distinct cellular types: natural killer-like cytotoxic T cell and true natural killer cell.台湾的肠道T细胞和自然杀伤细胞淋巴瘤，特别强调两种不同的细胞类型：自然杀伤样细胞毒性T细胞和真正的自然杀伤细胞。
Hum Pathol. 2008 Jul;39(7):1018-25. doi: 10.1016/j.humpath.2007.11.003. Epub 2008 May 14.
7
Clinical relevance of three subtypes of primary sinonasal lymphoma characterized by immunophenotypic analysis.通过免疫表型分析确定的原发性鼻窦淋巴瘤三种亚型的临床相关性。
Head Neck. 2004 Jul;26(7):584-93. doi: 10.1002/hed.20015.
8
Management of T-cell and natural-killer-cell neoplasms in Asia: consensus statement from the Asian Oncology Summit 2009.亚洲T细胞和自然杀伤细胞肿瘤的管理：2009年亚洲肿瘤学峰会共识声明
Lancet Oncol. 2009 Nov;10(11):1093-101. doi: 10.1016/S1470-2045(09)70265-7.
9
Human interleukin-10 expression in T/natural killer-cell lymphomas: association with anaplastic large cell lymphomas and nasal natural killer-cell lymphomas.人白细胞介素-10在T/自然杀伤细胞淋巴瘤中的表达：与间变性大细胞淋巴瘤和鼻型自然杀伤细胞淋巴瘤的关联。
Am J Pathol. 1998 Oct;153(4):1229-37. doi: 10.1016/S0002-9440(10)65667-2.
10
CD30 expression in extranodal natural killer/T-cell lymphoma, nasal type among 622 cases of mature T-cell and natural killer-cell lymphoma at a single institution in South China.中国南方一家机构622例成熟T细胞和自然杀伤细胞淋巴瘤中鼻型结外自然杀伤/T细胞淋巴瘤的CD30表达情况。
Chin J Cancer. 2017 May 10;36(1):43. doi: 10.1186/s40880-017-0212-9.

引用本文的文献

1
Emerging predictive biomarkers for novel therapeutics in peripheral T-cell and natural killer/T-cell lymphoma.外周 T 细胞和自然杀伤/T 细胞淋巴瘤新型治疗药物的新兴预测性生物标志物。
Front Immunol. 2023 Jan 26;14:1068662. doi: 10.3389/fimmu.2023.1068662. eCollection 2023.
2
Phase II Study of Gemcitabine, Peg-Asparaginase, Dexamethasone and Methotrexate Regimen for Newly Diagnosed Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: Final Analysis With Long-Term Follow-Up and Rational Research for the Combination.吉西他滨、聚乙二醇化天冬酰胺酶、地塞米松和甲氨蝶呤方案治疗新诊断的鼻型结外自然杀伤/T细胞淋巴瘤的II期研究：长期随访的最终分析及联合用药的合理性研究
Front Oncol. 2022 Jan 24;12:796738. doi: 10.3389/fonc.2022.796738. eCollection 2022.
3

本文引用的文献

1
Epstein-Barr virus-associated primary nodal T/NK-cell lymphoma shows a distinct molecular signature and copy number changes.EB 病毒相关原发性结内 T/NK 细胞淋巴瘤具有独特的分子特征和拷贝数改变。
Haematologica. 2018 Feb;103(2):278-287. doi: 10.3324/haematol.2017.180430. Epub 2017 Nov 2.
2
Sequential chemotherapy/radiotherapy was comparable with concurrent chemoradiotherapy for stage I/II NK/T-cell lymphoma.序贯化疗/放疗与同期放化疗在Ⅰ/Ⅱ期 NK/T 细胞淋巴瘤中疗效相当。
Ann Oncol. 2018 Jan 1;29(1):256-263. doi: 10.1093/annonc/mdx684.
3
Current treatment approaches for NK/T-cell lymphoma.
Towards Next Generation Biomarkers in Natural Killer/T-Cell Lymphoma.迈向自然杀伤/ T细胞淋巴瘤的新一代生物标志物
Life (Basel). 2021 Aug 16;11(8):838. doi: 10.3390/life11080838.
4
Clinical impact of lymphatic spread in patients with limited-stage upper aerodigestive tract NK/T cell lymphoma.局限期上消化道NK/T细胞淋巴瘤患者中淋巴转移的临床影响
Blood Res. 2021 Jun 30;56(2):72-78. doi: 10.5045/br.2021.2020328.
5
Whole-genome sequencing reveals potent therapeutic strategy for monomorphic epitheliotropic intestinal T-cell lymphoma.全基因组测序揭示了单形性上皮样肠道T细胞淋巴瘤的有效治疗策略。
Blood Adv. 2020 Oct 13;4(19):4769-4774. doi: 10.1182/bloodadvances.2020001782.
6
A clinicohaematological prognostic model for nasal-type natural killer/T-cell lymphoma: A multicenter study.鼻腔型自然杀伤/T 细胞淋巴瘤的临床血液学预后模型：一项多中心研究。
Sci Rep. 2019 Oct 18;9(1):14961. doi: 10.1038/s41598-019-51522-0.
7
Recurrent GNAQ mutation encoding T96S in natural killer/T cell lymphoma.自然杀伤/T 细胞淋巴瘤中 GNAQ 基因 T96S 反复突变。
Nat Commun. 2019 Sep 16;10(1):4209. doi: 10.1038/s41467-019-12032-9.
NK/T细胞淋巴瘤的当前治疗方法。
J Clin Exp Hematop. 2017 Dec 27;57(3):98-108. doi: 10.3960/jslrt.17018. Epub 2017 Jul 6.
4
The diagnosis and management of NK/T-cell lymphomas.NK/T细胞淋巴瘤的诊断与管理
J Hematol Oncol. 2017 Apr 14;10(1):85. doi: 10.1186/s13045-017-0452-9.
5
PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase.帕博利珠单抗的 PD1 阻断在 l-天冬酰胺酶治疗失败的复发或难治性 NK/T 细胞淋巴瘤中具有高度疗效。
Blood. 2017 Apr 27;129(17):2437-2442. doi: 10.1182/blood-2016-12-756841. Epub 2017 Feb 10.
6
Targeting CD38 in Refractory Extranodal Natural Killer Cell-T-Cell Lymphoma.靶向难治性结外自然杀伤细胞-T细胞淋巴瘤中的CD38
N Engl J Med. 2016 Oct 13;375(15):1501-1502. doi: 10.1056/NEJMc1605684.
7
Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study.结外自然杀伤T细胞淋巴瘤的遗传风险：一项全基因组关联研究。
Lancet Oncol. 2016 Sep;17(9):1240-7. doi: 10.1016/S1470-2045(16)30148-6. Epub 2016 Jul 25.
8
A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis.非蒽环类药物治疗后自然杀伤细胞淋巴瘤的预后指数：一项多中心回顾性分析。
Lancet Oncol. 2016 Mar;17(3):389-400. doi: 10.1016/S1470-2045(15)00533-1. Epub 2016 Feb 10.
9
JAK-STAT and G-protein-coupled receptor signaling pathways are frequently altered in epitheliotropic intestinal T-cell lymphoma.JAK-STAT和G蛋白偶联受体信号通路在上皮型肠道T细胞淋巴瘤中经常发生改变。
Leukemia. 2016 Jun;30(6):1311-9. doi: 10.1038/leu.2016.13. Epub 2016 Feb 8.
10
Complete remission in CD30-positive refractory extranodal NK/T-cell lymphoma with brentuximab vedotin.使用维布妥昔单抗治疗CD30阳性难治性结外NK/T细胞淋巴瘤实现完全缓解
Blood Res. 2015 Dec;50(4):254-6. doi: 10.5045/br.2015.50.4.254. Epub 2015 Dec 21.